Indeed, CLL patients with greater than 30% CD38+ B cells required more rigorous chemotherapy treatment regimens and a shorter time to first treatment [57], as well as displaying significantly shorter survival times, all suggesting a more aggressive disease course with clonal expression of CD38. Here, CD38 is linked to B-cell chronic lymphocytic leukemia.